Experimental drug combo targets brain cancer metabolism

NCT ID NCT03528642

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 40 participants aged 16 and older are being studied.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telaglenastat (CB-839) hydrochloride
What this could lead to: If it works, this could point toward a new treatment combination for certain brain tumors that may improve outcomes beyond standard therapy.
What could go wrong: This is an early phase 1b trial with only 40 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) astrocytoma, IDH-mutant, grade 2 astrocytoma, IDH-mutant, grade 3 diffuse astrocytoma follicular lymphoma IDH-mutant anaplastic astrocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTOMA IDH MUTANT GRADE 3 ASTROCYTOMA, IDH-MUTANT, GRADE 2

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.